Gapping up
In reaction to earnings/guidance:
- AVYA +11.2%, ZH +10%
Other news:
- VG +25.5% (Vonage to be acquired by Ericsson (ERIC) for $21.00 per share)
- AFMD +24.8% (announces interim clinical results from the investigator-initiated phase 1-2 study at The University of Texas MD Anderson Cancer Center, evaluating cbNK cells pre-complexed with Affimed's innate cell engager AFM13)
- PRVB +15.7% (provides regulatory update for Teplizumab)
- BLUE +9% (receives FDA Priority Review of Biologics License Application for beti-cel Gene Therapy)
- GENI +6.8% (Genius Sports announced a new agreement with FanDuel Group to provide a range of official NFL data, content, media products and trading services)
- BNTX +2.4% (BioNTech and Pfizer report follow-up data from Phase 3 trial of COVID-19 Vaccine)
- MRNA +2.2% (confirms CDC Advisory Committee recommendation for booster vaccination with Moderna's COVID-19 vaccine)
- RPRX +2.2% (acquires additional royalty interests in BioCryst Pharma (BCRX) therapeutics)
- PBYI +2% (Presents Data from the Neratinib Arm of the INSIGhT Trial at the 2021 SNO Annual Meeting)
- ACEL +2% (approves $200 mln common stock repurchase program)
- VOD +1.6% (in sympathy with Telecom Italia bid from KKR)
- TLYS +1% (declares a special cash dividend of $1.00/share)
- DPW +1% (to change name to BitNile Holdings and split into two public companies)
Analyst comments:
- CWK +5.6% (upgraded to Strong Buy from Outperform at Raymond James )
- ALNY +4.3% (upgraded to Buy from Neutral at Goldman)
- DCT +3.8% (upgraded to Overweight from Equal Weight at Barclays)
- DV +3.1% (upgraded to Buy from Hold at Truist)
- ADBE +1% (upgraded to Overweight from Neutral at Atlantic Equities)